INSM
Insmed Incorporated
Price Chart
Latest Quote
$104.47
+0.99 (+0.96%)
Current Price
| Previous Close | $103.48 |
| Open | $103.00 |
| Day High | $107.49 |
| Day Low | $101.75 |
| Volume | 1,893,312 |
Stock Information
| Shares Outstanding | 216.75M |
| Total Debt | $742.46M |
| Cash Equivalents | $1.22B |
| Revenue | $819.56M |
| Net Income | $-1.18B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $22.65B |
| EPS (TTM) | $-5.76 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $21.94B |
| Sales | $819.56M |
| Income | $-1.18B |
| Book/sh | $3.25 |
| Cash/sh | $5.64 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 3.88 |
| Current Ratio | 4.47 |
| Debt/Eq | 105.34 |
Returns & Margins
| ROA | -31.11% |
| ROE | -294.46% |
| Gross Margin | 81.81% |
| Operating Margin | -65.46% |
| Profit Margin | -144.44% |
Ownership
| Insider Ownership | 0.52% |
| Institutional Ownership | 105.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 756.02 |
| PEG | 1.09 |
| P/S | 27.63 |
| P/B | 32.10 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $197.05 |
Technical Indicators
| SMA20 | $100.18 |
| SMA50 | $115.19 |
| SMA200 | $152.74 |
| RSI | 49.51 |
| ATR | 5.8549 |
| Shares Float | 198.30M |
| Short Float | 9.95% |
| Short Ratio | 4.67 |
| Volatility | 0.77 |
| Rel Volume | 0.39 |
Performance History
| Week | +6.12% |
| Month | -4.04% |
| Quarter | -29.56% |
| 6 Months | -40.56% |
| YTD | -41.01% |
| Year | -1.35% |
| 3 Years | +416.95% |
| 5 Years | +257.42% |
| 10 Years | +1054.42% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $104.47 | 1,893,312 |
| 2026-06-24 | $103.46 | 3,136,900 |
| 2026-06-23 | $102.15 | 4,199,700 |
| 2026-06-22 | $98.61 | 4,257,400 |
| 2026-06-18 | $95.80 | 23,379,000 |
| 2026-06-17 | $98.45 | 3,472,900 |
| 2026-06-16 | $95.52 | 3,423,700 |
| 2026-06-15 | $97.46 | 3,788,600 |
| 2026-06-12 | $97.85 | 4,529,000 |
| 2026-06-11 | $96.72 | 5,105,200 |
| 2026-06-10 | $91.88 | 5,425,300 |
| 2026-06-09 | $99.04 | 4,240,900 |
| 2026-06-08 | $94.17 | 5,010,400 |
| 2026-06-05 | $94.22 | 7,956,300 |
| 2026-06-04 | $104.92 | 1,849,300 |
| 2026-06-03 | $103.86 | 2,978,400 |
| 2026-06-02 | $103.73 | 2,406,200 |
| 2026-06-01 | $106.03 | 3,357,500 |
| 2026-05-29 | $106.91 | 4,534,800 |
| 2026-05-28 | $108.37 | 2,230,800 |
| 2026-05-27 | $106.40 | 3,094,500 |
| 2026-05-26 | $108.87 | 2,273,700 |
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
đ° Latest News
Nebius and CoreWeave fall after Nasdaq 100 listing
Blockspace âĸ 2026-06-23T21:33:25Z
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-23T14:24:00Z
Should Insmedâs (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors?
Simply Wall St. âĸ 2026-06-23T00:13:53Z
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgeraldâs Target Raise?
Insider Monkey âĸ 2026-06-22T14:14:17Z
Nasdaq-100 Onboards 5 New Stocks in AI-Fueled Rebalancing
The Daily Upside âĸ 2026-06-22T04:01:00Z
Dear CoreWeave Stock Fans, Mark Your Calendars for June 22
Barchart âĸ 2026-06-17T18:11:34Z
Jim Cramer Says SaaS Companies Like Zscaler âHave Fallen Viciously Out of Favor on Wall Streetâ
Insider Monkey âĸ 2026-06-17T16:38:14Z
Stocks Rally on Hopes for a Near-term US-Iran Interim Peace Agreement
Barchart âĸ 2026-06-12T20:39:53Z
Stocks See Support from Hopes for a Near-term US-Iran Peace Agreement
Barchart âĸ 2026-06-12T15:51:42Z
Stocks See Support from Hopes for a Near-term US-Iran Agreement
Barchart âĸ 2026-06-12T14:28:13Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $112,489,000 | $79,781,000 | $60,046,000 | $49,848,000 |
| Cost Of Revenue | $122,938,000 | $85,742,000 | $65,573,000 | $55,126,000 |
| Total Revenue | $606,423,000 | $363,707,000 | $305,208,000 | $245,358,000 |
| Operating Revenue | $606,423,000 | $363,707,000 | $305,208,000 | $245,358,000 |
| Expenses | ||||
| Interest Expense | $77,579,000 | $80,258,000 | $76,256,000 | $22,455,000 |
| Total Expenses | $1,601,199,000 | $1,150,277,000 | $986,137,000 | $723,481,000 |
| Other Income Expense | $-193,178,000 | $-38,582,000 | $15,611,000 | $24,418,000 |
| Other Non Operating Income Expenses | $-1,841,000 | $29,000 | $1,856,000 | $-5,939,000 |
| Net Non Operating Interest Income Expense | $-83,795,000 | $-84,913,000 | $-81,694,000 | $-26,446,000 |
| Total Other Finance Cost | $6,216,000 | $6,884,000 | $7,320,000 | $3,991,000 |
| Interest Expense Non Operating | $77,579,000 | $80,258,000 | $76,256,000 | $22,455,000 |
| Operating Expense | $1,478,261,000 | $1,064,535,000 | $920,564,000 | $668,355,000 |
| General And Administrative Expense | $701,167,000 | $461,116,000 | $344,501,000 | $265,784,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,276,775,000 | $-913,772,000 | $-749,567,000 | $-481,534,000 |
| Net Interest Income | $-83,795,000 | $-84,913,000 | $-81,694,000 | $-26,446,000 |
| Interest Income | $0 | $2,229,000 | $1,882,000 | - |
| Normalized Income | $-1,125,618,770 | $-883,269,310 | $-760,433,450 | $-511,891,000 |
| Net Income From Continuing And Discontinued Operation | $-1,276,775,000 | $-913,772,000 | $-749,567,000 | $-481,534,000 |
| Total Operating Income As Reported | $-1,246,769,000 | $-878,252,000 | $-709,626,000 | $-457,321,000 |
| Net Income Common Stockholders | $-1,276,775,000 | $-913,772,000 | $-749,567,000 | $-481,534,000 |
| Net Income | $-1,276,775,000 | $-913,772,000 | $-749,567,000 | $-481,534,000 |
| Net Income Including Noncontrolling Interests | $-1,276,775,000 | $-913,772,000 | $-749,567,000 | $-481,534,000 |
| Net Income Continuous Operations | $-1,276,775,000 | $-913,772,000 | $-749,567,000 | $-481,534,000 |
| Pretax Income | $-1,271,749,000 | $-910,065,000 | $-747,012,000 | $-480,151,000 |
| Special Income Charges | $-251,993,000 | $-91,682,000 | $-28,697,000 | $20,802,000 |
| Interest Income Non Operating | $0 | $2,229,000 | $1,882,000 | - |
| Operating Income | $-994,776,000 | $-786,570,000 | $-680,929,000 | $-478,123,000 |
| Depreciation Amortization Depletion Income Statement | $6,001,000 | $5,052,000 | $5,052,000 | $5,053,000 |
| Depreciation And Amortization In Income Statement | $6,001,000 | $5,052,000 | $5,052,000 | $5,053,000 |
| Amortization Of Intangibles Income Statement | $6,001,000 | $5,052,000 | $5,052,000 | $5,053,000 |
| Gross Profit | $483,485,000 | $277,965,000 | $239,635,000 | $190,232,000 |
| Per Share | ||||
| Diluted EPS | $-6.42 | $-5.57 | $-5.34 | $-3.91 |
| Basic EPS | $-6.42 | $-5.57 | $-5.34 | $-3.91 |
| Other | ||||
| Tax Effect Of Unusual Items | $-40,180,770 | $-8,108,310 | $2,888,550 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-986,383,000 | $-780,183,000 | $-673,932,000 | $-477,722,000 |
| Total Unusual Items | $-191,337,000 | $-38,611,000 | $13,755,000 | $30,357,000 |
| Total Unusual Items Excluding Goodwill | $-191,337,000 | $-38,611,000 | $13,755,000 | $30,357,000 |
| Reconciled Depreciation | $16,450,000 | $11,013,000 | $10,579,000 | $10,331,000 |
| EBITDA (Bullshit earnings) | $-1,177,720,000 | $-818,794,000 | $-660,177,000 | $-447,365,000 |
| EBIT | $-1,194,170,000 | $-829,807,000 | $-670,756,000 | $-457,696,000 |
| Diluted Average Shares | $199,014,000 | $164,043,000 | $140,433,000 | $123,035,000 |
| Basic Average Shares | $199,014,000 | $164,043,000 | $140,433,000 | $123,035,000 |
| Diluted NI Availto Com Stockholders | $-1,276,775,000 | $-913,772,000 | $-749,567,000 | $-481,534,000 |
| Tax Provision | $5,026,000 | $3,707,000 | $2,555,000 | $1,383,000 |
| Restructuring And Mergern Acquisition | $251,993,000 | $91,682,000 | $28,697,000 | $-20,802,000 |
| Gain On Sale Of Security | $60,656,000 | $53,071,000 | $42,452,000 | $9,555,000 |
| Amortization | $6,001,000 | $5,052,000 | $5,052,000 | $5,053,000 |
| Research And Development | $771,093,000 | $598,367,000 | $571,011,000 | $397,518,000 |
| Selling General And Administration | $701,167,000 | $461,116,000 | $344,501,000 | $265,784,000 |
| Other Gand A | $370,005,000 | $243,457,000 | $187,677,000 | $141,768,000 |
| Salaries And Wages | $331,162,000 | $217,659,000 | $156,824,000 | $124,016,000 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $505,215,000 | $90,617,000 | $-531,737,000 | $-116,915,000 |
| Total Assets | $2,264,558,000 | $2,025,231,000 | $1,329,837,000 | $1,656,435,000 |
| Total Non Current Assets | $470,350,000 | $403,570,000 | $400,774,000 | $383,052,000 |
| Other Non Current Assets | $97,378,000 | $93,226,000 | $96,574,000 | $76,104,000 |
| Goodwill And Other Intangible Assets | $233,761,000 | $194,762,000 | $199,814,000 | $204,866,000 |
| Other Intangible Assets | $97,651,000 | $58,652,000 | $63,704,000 | $68,756,000 |
| Current Assets | $1,794,208,000 | $1,621,661,000 | $929,063,000 | $1,273,383,000 |
| Other Current Assets | $91,236,000 | $37,245,000 | $24,179,000 | $25,468,000 |
| Inventory | $132,068,000 | $98,578,000 | $83,248,000 | $69,922,000 |
| Receivables | $140,857,000 | $52,012,000 | $41,189,000 | $29,713,000 |
| Accounts Receivable | $140,857,000 | $52,012,000 | $41,189,000 | $29,713,000 |
| Cash And Cash Equivalents | $510,445,000 | $555,030,000 | $482,374,000 | $1,074,036,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $30,519,000 | $548,352,000 | $672,939,000 | $51,214,000 |
| Long Term Debt And Capital Lease Obligation | $573,857,000 | $1,136,558,000 | $1,193,352,000 | $1,169,739,000 |
| Long Term Debt | $540,964,000 | $1,103,382,000 | $1,155,313,000 | $1,125,250,000 |
| Current Debt And Capital Lease Obligation | $12,814,000 | $12,319,000 | $10,642,000 | $8,126,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,525,582,000 | $1,739,852,000 | $1,661,760,000 | $1,568,484,000 |
| Total Non Current Liabilities Net Minority Interest | $1,056,708,000 | $1,442,324,000 | $1,436,131,000 | $1,378,241,000 |
| Other Non Current Liabilities | $482,851,000 | $305,766,000 | $242,779,000 | $208,502,000 |
| Current Liabilities | $468,874,000 | $297,528,000 | $225,629,000 | $190,243,000 |
| Payables And Accrued Expenses | $344,546,000 | $204,897,000 | $159,354,000 | $139,377,000 |
| Interest Payable | $0 | $359,000 | $2,175,000 | $6,340,000 |
| Payables | $103,457,000 | $83,534,000 | $74,414,000 | $57,320,000 |
| Other Payable | $23,550,000 | $10,501,000 | $9,021,000 | $6,859,000 |
| Accounts Payable | $79,907,000 | $73,033,000 | $65,393,000 | $50,461,000 |
| Current Deferred Liabilities | - | $24,700,000 | $6,700,000 | $10,700,000 |
| Equity | ||||
| Common Stock Equity | $738,976,000 | $285,379,000 | $-331,923,000 | $87,951,000 |
| Total Equity Gross Minority Interest | $738,976,000 | $285,379,000 | $-331,923,000 | $87,951,000 |
| Stockholders Equity | $738,976,000 | $285,379,000 | $-331,923,000 | $87,951,000 |
| Gains Losses Not Affecting Retained Earnings | $1,461,000 | $-2,289,000 | $-745,000 | $756,000 |
| Other Equity Adjustments | $1,461,000 | $-2,289,000 | $-745,000 | $756,000 |
| Retained Earnings | $-5,636,692,000 | $-4,359,917,000 | $-3,446,145,000 | $-2,696,578,000 |
| Other | ||||
| Ordinary Shares Number | $214,255,853 | $179,382,635 | $147,977,960 | $135,653,731 |
| Share Issued | $214,255,853 | $179,382,635 | $147,977,960 | $135,653,731 |
| Tangible Book Value | $505,215,000 | $90,617,000 | $-531,737,000 | $-116,915,000 |
| Invested Capital | $1,279,940,000 | $1,388,761,000 | $823,390,000 | $1,213,201,000 |
| Working Capital | $1,325,334,000 | $1,324,133,000 | $703,434,000 | $1,083,140,000 |
| Capital Lease Obligations | $45,707,000 | $45,495,000 | $48,681,000 | $52,615,000 |
| Total Capitalization | $1,279,940,000 | $1,388,761,000 | $823,390,000 | $1,213,201,000 |
| Additional Paid In Capital | $6,372,064,000 | $4,645,791,000 | $3,113,487,000 | $2,782,416,000 |
| Capital Stock | $2,143,000 | $1,794,000 | $1,480,000 | $1,357,000 |
| Common Stock | $2,143,000 | $1,794,000 | $1,480,000 | $1,357,000 |
| Long Term Capital Lease Obligation | $32,893,000 | $33,176,000 | $38,039,000 | $44,489,000 |
| Current Capital Lease Obligation | $12,814,000 | $12,319,000 | $10,642,000 | $8,126,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $111,514,000 | $80,312,000 | $48,933,000 | $32,040,000 |
| Current Accrued Expenses | $241,089,000 | $121,363,000 | $84,940,000 | $82,057,000 |
| Goodwill | $136,110,000 | $136,110,000 | $136,110,000 | $136,110,000 |
| Net PPE | $139,211,000 | $115,582,000 | $104,386,000 | $102,082,000 |
| Accumulated Depreciation | $-60,755,000 | $-50,306,000 | $-44,628,000 | $-39,445,000 |
| Gross PPE | $199,966,000 | $165,888,000 | $149,014,000 | $141,527,000 |
| Leases | $53,400,000 | $38,058,000 | $38,049,000 | $37,057,000 |
| Construction In Progress | $42,410,000 | $51,127,000 | $35,449,000 | $29,529,000 |
| Other Properties | $76,732,000 | $63,619,000 | $62,998,000 | $63,197,000 |
| Machinery Furniture Equipment | $15,024,000 | $13,084,000 | $12,518,000 | $11,744,000 |
| Buildings And Improvements | $10,437,000 | $0 | - | - |
| Land And Improvements | $1,963,000 | $0 | - | - |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $60,099,000 | $38,964,000 | $25,206,000 | $20,217,000 |
| Work In Process | $41,346,000 | $39,932,000 | $33,480,000 | $22,460,000 |
| Raw Materials | $30,623,000 | $19,682,000 | $24,562,000 | $27,245,000 |
| Other Short Term Investments | $919,602,000 | $878,796,000 | $298,073,000 | $74,244,000 |
| Investments And Advances | - | - | - | $0 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-967,575,000 | $-705,805,000 | $-549,535,000 | $-410,317,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-935,014,000 | $-683,882,000 | $-536,247,000 | $-400,439,000 |
| Cash Flow From Continuing Operating Activities | $-935,014,000 | $-683,882,000 | $-536,247,000 | $-400,439,000 |
| Operating Gains Losses | - | $236,000 | $-320,000 | $1,526,000 |
| Investing Activities | ||||
| Capital Expenditure | $-32,561,000 | $-21,923,000 | $-13,288,000 | $-9,878,000 |
| Investing Cash Flow | $-64,575,000 | $-583,175,000 | $-223,604,000 | $-34,584,000 |
| Cash Flow From Continuing Investing Activities | $-64,575,000 | $-583,175,000 | $-223,604,000 | $-34,584,000 |
| Net Other Investing Changes | $-30,000,000 | - | $3,417,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $823,282,000 | $1,084,124,000 | $152,475,000 | $292,153,000 |
| Financing Cash Flow | $954,073,000 | $1,341,020,000 | $168,439,000 | $793,273,000 |
| Cash Flow From Continuing Financing Activities | $954,073,000 | $1,341,020,000 | $168,439,000 | $793,273,000 |
| Net Common Stock Issuance | $823,282,000 | $1,084,124,000 | $152,475,000 | $292,153,000 |
| Common Stock Issuance | $823,282,000 | $1,084,124,000 | $152,475,000 | $292,153,000 |
| Net Other Financing Charges | - | $-3,737,000 | $-1,218,000 | $132,217,000 |
| Other | ||||
| Repayment Of Debt | $-4,926,000 | $-2,610,000 | $-1,217,000 | $-601,000 |
| Issuance Of Debt | $0 | $150,000,000 | $0 | $350,000,000 |
| Interest Paid Supplemental Data | $55,353,000 | $40,567,000 | $35,787,000 | $10,157,000 |
| Income Tax Paid Supplemental Data | $4,141,000 | $2,499,000 | $1,955,000 | $1,717,000 |
| End Cash Position | $510,445,000 | $555,030,000 | $482,374,000 | $1,074,036,000 |
| Beginning Cash Position | $555,030,000 | $482,374,000 | $1,074,036,000 | $716,782,000 |
| Effect Of Exchange Rate Changes | $931,000 | $-1,307,000 | $-250,000 | $-996,000 |
| Changes In Cash | $-45,516,000 | $73,963,000 | $-591,412,000 | $358,250,000 |
| Proceeds From Stock Option Exercised | $135,717,000 | $113,243,000 | $18,399,000 | $19,504,000 |
| Net Issuance Payments Of Debt | $-4,926,000 | $147,390,000 | $-1,217,000 | $349,399,000 |
| Net Long Term Debt Issuance | $-4,926,000 | $147,390,000 | $-1,217,000 | $349,399,000 |
| Long Term Debt Payments | $-4,926,000 | $-2,610,000 | $-1,217,000 | $-601,000 |
| Long Term Debt Issuance | $0 | $150,000,000 | $0 | $350,000,000 |
| Net Investment Purchase And Sale | $-2,014,000 | $-561,252,000 | $-213,733,000 | $-24,706,000 |
| Sale Of Investment | $2,090,000,000 | $1,016,000,000 | $375,000,000 | $75,000,000 |
| Purchase Of Investment | $-2,092,014,000 | $-1,577,252,000 | $-588,733,000 | $-99,706,000 |
| Net PPE Purchase And Sale | $-32,561,000 | $-21,923,000 | $-13,288,000 | $-9,878,000 |
| Purchase Of PPE | $-32,561,000 | $-21,923,000 | $-13,288,000 | $-9,878,000 |
| Change In Working Capital | $-80,299,000 | $-3,177,000 | $-39,218,000 | $6,575,000 |
| Change In Other Current Liabilities | $-4,992,000 | $-11,946,000 | $-10,988,000 | $-12,584,000 |
| Change In Other Current Assets | $-2,123,000 | $8,335,000 | $-20,074,000 | $-25,243,000 |
| Change In Payables And Accrued Expense | $100,073,000 | $44,592,000 | $15,155,000 | $50,011,000 |
| Change In Prepaid Assets | $-53,431,000 | $-14,182,000 | $2,265,000 | $2,528,000 |
| Change In Inventory | $-31,519,000 | $-17,044,000 | $-13,613,000 | $-1,714,000 |
| Change In Receivables | $-88,307,000 | $-12,932,000 | $-11,963,000 | $-6,423,000 |
| Changes In Account Receivables | $-88,307,000 | $-12,932,000 | $-11,963,000 | $-6,423,000 |
| Other Non Cash Items | $291,248,000 | $144,143,000 | $176,884,000 | $4,977,000 |
| Stock Based Compensation | $152,710,000 | $96,835,000 | $74,778,000 | $57,686,000 |
| Amortization Of Securities | $-38,348,000 | $-19,160,000 | $-9,383,000 | $0 |
| Depreciation Amortization Depletion | $16,450,000 | $11,013,000 | $10,579,000 | $10,331,000 |
| Depreciation And Amortization | $16,450,000 | $11,013,000 | $10,579,000 | $10,331,000 |
| Amortization Cash Flow | $6,001,000 | $5,052,000 | $5,052,000 | $5,053,000 |
| Amortization Of Intangibles | $6,001,000 | $5,052,000 | $5,052,000 | $5,053,000 |
| Depreciation | $10,449,000 | $5,961,000 | $5,527,000 | $5,278,000 |
| Net Income From Continuing Operations | $-1,276,775,000 | $-913,772,000 | $-749,567,000 | $-481,534,000 |
| Gain Loss On Investment Securities | - | $236,000 | $-320,000 | $1,526,000 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
| Gain Loss On Sale Of Business | - | - | $76,481,000 | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | - |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-06-21